サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1433619

オリゴヌクレオチド合成の世界市場規模、シェア、動向分析レポート：製品・サービス別、用途別、地域別、セグメント別予測（2024年～2030年）

Oligonucleotide Synthesis Market Size, Share & Trends Analysis Report By Product & Service (Oligonucleotides, Equipment/Synthesizer), By Application (PCR Primers, PCR Assays & Panels), By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 135 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
オリゴヌクレオチド合成の世界市場規模、シェア、動向分析レポート：製品・サービス別、用途別、地域別、セグメント別予測（2024年～2030年）
出版日: 2024年01月24日
発行: Grand View Research
ページ情報: 英文 135 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

オリゴヌクレオチド合成市場の成長と動向：

世界のオリゴヌクレオチド合成の市場規模は、2030年までに85億3,000万米ドルに達し、2024年～2030年にCAGR13.21％で拡大すると予測されています。 臨床試験中のオリゴヌクレオチド治療薬の強力なパイプライン、遺伝子編集技術の進歩、バイオテクノロジー企業による研究開発費の増加は、市場成長を促進する主な要因の一部です。

オリゴヌクレオチド治療薬の参加企業は、臨床試験の後期段階にあり、予測期間中に承認・商業化される見込みです。企業はオリゴヌクレオチドベースの治療薬を開発するための投資を増やしています。2023年10月、GSK plcとアローヘッド・ファーマシューティカルズは、ジョンソン・エンド・ジョンソンのヤンセン・ファーマシューティカルズ・インク（ヤンセン）と、JNJ-3989を開発・商業化する独占的な世界的権利をGSKに譲渡する契約を締結したと発表しました。ヤンセンは当初、2018年にアローヘッドからJNJ-3989（以前はARO-HBV）を導入しました。老舗製薬企業による同様の取り組みが、予測期間中の市場成長を促進すると予想されます。

ラボについてはメディケイド＆メディケアサービスセンター（Centers for Medicaid &Medicare Services）、マーケティングについては連邦取引委員会（Federal Trade Commission）、キット＆情報についてはFDAといった政府機関では、ゲノミクス＆遺伝子検査の安全で適切かつ正確な応用の監視に関与しており、ゲノミクスの成功に重要な役割を果たしています。NIHやウェルカム・トラストといった国際的な資金提供機関も遺伝子研究に資金を提供しており、先進経済諸国や新興経済諸国におけるゲノム研究の活性化が期待されています。

2021年5月、英国政府はゲノミクス研究とデータ駆動型イニシアチブのために4,340万米ドル（3,700万英ポンド）の資金提供を発表し、2019年9月に開始されたUK Functional Genomics InitiativeとGenome UK Implementation Planを通じて提供されました。ゲノムUK戦略は、新生児シーケンスの潜在的価値を調査するために1,990万米ドル（1,700万英ポンド）を受け取るGenomics Englandプロジェクトの助けを借りて実施されます。

オリゴヌクレオチド合成市場レポートハイライト：

  • 製品・サービス別では、サービス分野が2023年に37.0%以上のシェアを占め、市場を独占しました。
  • 用途別では、PCRプライマーセグメントが2023年に最大の市場シェアを占めました。特定のDNAまたはRNA配列の増幅に極めて重要な役割を果たすことから、同市場では不可欠な構成要素となっています。
  • 北米は、主要企業のプレゼンス向上、様々な用途における合成DNA・RNA配列の需要増加、有利な規制シナリオなどの要因により、市場を独占しました。
  • 2023年5月、GenScript社は中国江蘇省鎮江市のライフサイエンス施設を拡張し、研究開発・前臨床用途に合わせた迅速で高純度のオリゴヌクレオチド・ペプチド合成サービスを提供します。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 オリゴヌクレオチド合成市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19感染症の影響分析

第4章 オリゴヌクレオチド合成市場：製品・サービスの推定・動向分析

  • 製品・サービスの市場シェア（2023年・2030年）
  • 市場規模、予測、動向分析（2018年～2030年）

第5章 オリゴヌクレオチド合成市場：用途の推定・動向分析

  • 用途の市場シェア（2023年・2030年）
  • 市場規模、予測、動向分析（2018年～2030年）

第6章 オリゴヌクレオチド合成市場：地域の推定・動向分析

  • 地域市場シェア分析（2023年・2030年）
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 企業/競合の分類
  • 戦略マッピング
  • 企業の市況分析（2023年）
  • 企業プロファイル・一覧表
    • Thermo Fisher Scientific, Inc.
    • Merck KGaA
    • Danaher Corporation
    • Dharmacon Inc.
    • Agilent Technologies
    • Bio-synthesis
    • Kaneka Eurogentec SA
    • LGC Biosearch Technologies
    • Biolegio
    • Twist Bioscience
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 Global oligonucleotide synthesis market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America oligonucleotide synthesis market, by country, 2018 - 2030 (USD Million)
  • Table 4 North America oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 5 North America oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 7 U.S. oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 8 Canada oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 9 Canada oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 10 Europe oligonucleotide synthesis market, by country, 2018 - 2030 (USD Million)
  • Table 11 Europe oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 12 Europe oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 13 Germany oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 14 Germany oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 15 UK oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 16 UK oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 17 France oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 18 France oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 19 Italy oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 20 Italy oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 21 Spain oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 22 Spain oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 23 Denmark oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 24 Denmark oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 25 Sweden oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 26 Sweden oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 27 Norway oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 28 Norway oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific oligonucleotide synthesis market, by country, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 32 China oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 33 China oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 34 Japan oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 35 Japan oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 36 India oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 37 India oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 38 South Korea oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 39 South Korea oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 40 Australia oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 41 Australia oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 42 Thailand oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 43 Thailand oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 44 Latin America oligonucleotide synthesis market, by country, 2018 - 2030 (USD Million)
  • Table 45 Latin America oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 46 Latin America oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 47 Brazil oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 48 Brazil oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 49 Mexico oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 50 Mexico oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 51 Argentina oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 52 Argentina oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 53 MEA oligonucleotide synthesis market, by country, 2018 - 2030 (USD Million)
  • Table 54 MEA oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 55 MEA oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 56 South Africa oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 57 South Africa oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 60 UAE oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 61 UAE oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 62 Kuwait oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 63 Kuwait oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Oligonucleotide synthesis market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Synthetic biology market value, 2023 (USD billion)
  • Fig. 16 Market trends & outlook
  • Fig. 17 Top investors in drug R&D as a percentage of net sales (2019)
  • Fig. 18 PESTEL analysis
  • Fig. 19 Porter's five forces analysis
  • Fig. 20 Oligonucleotide synthesis market: Product & service outlook & key takeaways
  • Fig. 21 Oligonucleotide synthesis market: Product & service movement analysis
  • Fig. 22 Oligonucleotides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 DNA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Column-based market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Array-based market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 RNA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Column-based market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Array-based market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Short RNA oligos (<65 nt) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Long RNA oligos (>65 nt) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 CRISPR (sgRNA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Equipment/synthesizer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Reagents market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 DNA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Custom oligo synthesis services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 25 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 50 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 200 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 1,000 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 10,000 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Modification services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Purification services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 RNA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Custom oligo synthesis services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 25 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 100 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 1,000 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 10,000 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Modification services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Purification services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Oligonucleotide synthesis market: Application outlook & key takeaways
  • Fig. 53 Oligonucleotide synthesis market: Application movement analysis
  • Fig. 54 PCR primers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 PCR assays and panels market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Sequencing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 DNA microarrays market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Fluorescence In Situ Hybridization (FISH) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Antisense oligonucleotides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Other applications market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Regional marketplace outlook, 2023 & 2030, (USD Million)
  • Fig. 62 Regional marketplace: Key takeaways
  • Fig. 63 North America oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 U.S. key country dynamics
  • Fig. 65 U.S. oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Canada key country dynamics
  • Fig. 67 Canada oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Europe oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 UK key country dynamics
  • Fig. 70 UK oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Germany key country dynamics
  • Fig. 72 Germany oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 France key country dynamics
  • Fig. 74 France oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Spain key country dynamics
  • Fig. 76 Spain oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Italy key country dynamics
  • Fig. 78 Italy oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Denmark key country dynamics
  • Fig. 80 Denmark oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Sweden key country dynamics
  • Fig. 82 Sweden oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Norway key country dynamics
  • Fig. 84 Norway oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Asia Pacific oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Japan key country dynamics
  • Fig. 87 Japan oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 China key country dynamics
  • Fig. 89 China oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 India key country dynamics
  • Fig. 91 India oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Australia Key country dynamics
  • Fig. 93 Australia oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Thailand key country dynamics
  • Fig. 95 Thailand oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 South Korea key country dynamics
  • Fig. 97 South Korea oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Latin America oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Brazil key country dynamics
  • Fig. 100 Brazil oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Mexico key country dynamics
  • Fig. 102 Mexico oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Argentina key country dynamics
  • Fig. 104 Argentina oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 MEA oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 South Africa key country dynamics
  • Fig. 107 South Africa oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 Saudi Arabia key country dynamics
  • Fig. 109 Saudi Arabia oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 UAE key country dynamics
  • Fig. 111 UAE oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 112 Kuwait key country dynamics
  • Fig. 113 Kuwait oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 114 Market participant categorization
  • Fig. 115 Global oligonucleotide synthesis market position analysis, 2023
  • Fig. 116 Strategic framework
目次
Product Code: GVR-2-68038-593-9

Oligonucleotide Synthesis Market Growth & Trends:

The global oligonucleotide synthesis market size is projected to reach USD 8.53 billion by 2030, registering a CAGR of 13.21% from 2024 to 2030, according to a new report by Grand View Research, Inc. The strong pipeline of oligonucleotide therapeutics in clinical trials, advancements in gene editing technologies, and increasing R&D spending by biotechnology companies are some of the major factors driving the market growth.

Oligonucleotide therapeutics participants are present in the late stages of clinical trials and are expected to be approved & commercialized over the forecast period. Companies have increased investments to develop oligonucleotide-based therapeutics. In October 2023, GSK plc and Arrowhead Pharmaceuticals announced a contract with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to assign GSK exclusive worldwide rights to develop and commercialize JNJ-3989. Janssen initially in-licensed JNJ-3989 (previously ARO-HBV) from Arrowhead in 2018. Similar initiatives by well-established pharmaceutical companies are anticipated to drive market growth over the forecast period.

Government bodies, such as the Centers for Medicaid & Medicare Services for labs, the Federal Trade Commission for marketing, and the FDA for kits & information, have played a key role in the success of genomics, as they have been involved in monitoring the safe, appropriate, and accurate application of genomics & genetic tests. International funding bodies, such as NIH and Wellcome Trust, are engaged in providing funds for genetic studies, which is expected to fuel genomic studies in developed and emerging economies.

In May 2021, the UK government announced a funding of USD 43.4 million (GBP 37 million) for genomics research and data-driven initiatives, delivered via the UK Functional Genomics Initiative and Genome UK Implementation Plan, which was started in September 2019. The Genome UK strategy will be implemented with the help of the Genomics England project, which will receive USD 19.9 million (GBP 17 million) to investigate the potential value of newborn sequencing.

Oligonucleotide Synthesis Market Report Highlights:

  • Based on product & services, the service segment dominated the market with more than 37.0% share in 2023 owing to the growing demand for specialized services and increasing number of demands for outsourcing services
  • Based on application, the PCR primers segment held the largest market share in 2023. Their crucial role in amplifying specific DNA or RNA sequences makes them an essential component of the market
  • North America dominated the market owing to factors such as increasing the presence of key players, increasing demand for synthetic DNA & RNA sequences in various applications, and favorable regulatory scenario
  • In May 2023, GenScript expanded its life sciences facility in Zhenjiang, Jiangsu, China, to offer a rapid, high-purity oligonucleotide and peptide synthesis service tailored for research & development as well as preclinical applications.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product & service
    • 1.2.2. Application
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Landscape Insights

Chapter 3. Oligonucleotide Synthesis Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Strong pipeline of oligonucleotide therapeutics in clinical trials
      • 3.2.1.2. Changing regulatory environments for genetic research and its applications in healthcare
      • 3.2.1.3. High R&D spending of pharmaceutical & biotechnology companies
      • 3.2.1.4. Increased public-private spending on genomics
      • 3.2.1.5. Technological advancements in gene editing technologies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Need for advanced oligo synthesis solutions
      • 3.2.2.2. High cost associated with genomics research
      • 3.2.2.3. Lack of skilled professionals and research support in undeveloped countries
  • 3.3. Business Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Oligonucleotide Synthesis Market: Product & Service Estimates & Trend Analysis

  • 4.1. Product & Service Market Share, 2023 & 2030
  • 4.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 4.2.1. Oligonucleotides
      • 4.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.2. DNA
      • 4.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.2.2. Column-based
      • 4.2.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.2.3. Array-based
      • 4.2.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.3. RNA
      • 4.2.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.3.2. By Technology
      • 4.2.1.3.2.1. Column-based
      • 4.2.1.3.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.3.2.2. Array-based
      • 4.2.1.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.3.3. By Type
      • 4.2.1.3.3.1. Short RNA Oligos (<65 nt)
      • 4.2.1.3.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.3.3.2. Long RNA Oligos (>65 nt)
      • 4.2.1.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.3.3.3. CRISPR (sgRNA)
      • 4.2.1.3.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.2.2. Equipment/Synthesizer
      • 4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.2.3. Reagents
      • 4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.2.4. Services
      • 4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2. DNA
      • 4.2.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.2. Custom oligo synthesis services
      • 4.2.4.2.2.1. 25 nmol
      • 4.2.4.2.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.2.2. 50 nmol
      • 4.2.4.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.2.3. 200 nmol
      • 4.2.4.2.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.2.4. 1000 nmol
      • 4.2.4.2.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.2.5. 10000 nmol
      • 4.2.4.2.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.3. Modification services
      • 4.2.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.4. Purification services
      • 4.2.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3. RNA
      • 4.2.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3.2. Custom oligo synthesis services
      • 4.2.4.3.2.1. 25 nmol
      • 4.2.4.3.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3.2.2. 100 nmol
      • 4.2.4.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3.2.3. 1000 nmol
      • 4.2.4.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3.2.4. 10000 nmol
      • 4.2.4.3.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3.3. Modification services
      • 4.2.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3.4. Purification services
      • 4.2.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Oligonucleotide Synthesis Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2023 & 2030
  • 5.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 5.2.1. PCR primers
      • 5.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.1.2. Academic research institutes
      • 5.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.1.2.2. Diagnostic laboratories
      • 5.2.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.1.2.3. Pharmaceutical - biotechnology companies
      • 5.2.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.2. PCR assays and panels
      • 5.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.2.2. Academic research institutes
      • 5.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.2.2.2. Diagnostic laboratories
      • 5.2.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.2.2.3. Pharmaceutical - biotechnology companies
      • 5.2.2.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.3. Sequencing
      • 5.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.3.2. Academic research institutes
      • 5.2.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.3.2.2. Diagnostic laboratories
      • 5.2.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.3.2.3. Pharmaceutical - biotechnology companies
      • 5.2.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.4. DNA microarrays
      • 5.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.4.2. Academic research institutes
      • 5.2.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.4.2.2. Diagnostic laboratories
      • 5.2.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.4.2.3. Pharmaceutical - biotechnology companies
      • 5.2.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.5. Fluorescence in situ hybridization (FISH)
      • 5.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.5.2. Academic research institutes
      • 5.2.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.5.2.2. Diagnostic laboratories
      • 5.2.5.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.5.2.3. Pharmaceutical - biotechnology companies
      • 5.2.5.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.6. Antisense oligonucleotides
      • 5.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.6.2. Academic research institutes
      • 5.2.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.6.2.2. Diagnostic laboratories
      • 5.2.6.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.6.2.3. Pharmaceutical - biotechnology companies
      • 5.2.6.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.7. Other applications
      • 5.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Oligonucleotide Synthesis Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. North America
    • 6.2.1. U.S.
      • 6.2.1.1. Key country dynamics
      • 6.2.1.2. Regulatory framework
      • 6.2.1.3. Competitive scenario
      • 6.2.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.2.2. Canada
      • 6.2.2.1. Key country dynamics
      • 6.2.2.2. Regulatory framework
      • 6.2.2.3. Competitive scenario
      • 6.2.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. UK
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Germany
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. France
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.4. Italy
      • 6.3.4.1. Key country dynamics
      • 6.3.4.2. Regulatory framework
      • 6.3.4.3. Competitive scenario
      • 6.3.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.5. Spain
      • 6.3.5.1. Key country dynamics
      • 6.3.5.2. Regulatory framework
      • 6.3.5.3. Competitive scenario
      • 6.3.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.6. Norway
      • 6.3.6.1. Key country dynamics
      • 6.3.6.2. Regulatory framework
      • 6.3.6.3. Competitive scenario
      • 6.3.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.7. Sweden
      • 6.3.7.1. Key country dynamics
      • 6.3.7.2. Regulatory framework
      • 6.3.7.3. Competitive scenario
      • 6.3.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.8. Denmark
      • 6.3.8.1. Key country dynamics
      • 6.3.8.2. Regulatory framework
      • 6.3.8.3. Competitive scenario
      • 6.3.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Japan
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. China
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. India
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Australia
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Thailand
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Brazil
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Mexico
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. MEA
    • 6.6.1. South Africa
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Saudi Arabia
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. UAE
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Kuwait
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company/Competition Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Position Analysis, 2023
  • 7.4. Company Profiles/Listing
    • 7.4.1. Thermo Fisher Scientific, Inc.
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Merck KGaA
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Danaher Corporation
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Dharmacon Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Agilent Technologies
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Bio-synthesis
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Kaneka Eurogentec S.A
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. LGC Biosearch Technologies
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Biolegio
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Twist Bioscience
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives